This content was funded by Johnson & Johnson and is intended for educational and scientific exchange purposes. Amivantamab plus lazertinib is not approved by the US Food and Drug Administration for the treatment of atypical EGFR-mutated NSCLC; it is approved for the first-line treatment of adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations. This content includes discussion of investigational and unapproved uses. The data presented do not establish safety or efficacy for any unapproved use, and this content is not intended to promote or recommend any unapproved use. Consult the full Prescribing Information for amivantamab and lazertinib for approved indications and complete safety information.
Atypical EGFR mutations (exon 18 G719X, exon 20 S768I, exon 21 L861Q) account for approximately 5–10% of all EGFR mutations in non-small cell lung cancer (NSCLC), representing a distinct population with unmet needs. This infographic outlines who these patients are, the current treatment options, and the outcomes reported with current options.
The infographic also reviews the efficacy and safety of first-line amivantamab + lazertinib in CHRYSALIS-2 Cohort C, a Phase I/Ib, single-arm, open-label study in treatment-naïve patients with atypical EGFR mutations. Additional sections cover the multimodal EGFR/MET mechanism of action, what the ASCO Living Guideline recommends as first-line options for atypical EGFR-mutated NSCLC, and key study limitations.
